- Home
- ITOC vs BCAB Comparison
ITOC vs BCAB Comparison
Compare ITOC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | BCAB |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | China | United States |
| Employees | 7 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITOC | BCAB |
|---|---|---|
| Price | $0.27 | $3.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.3K | 38.8K |
| Earning Date | 03-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.12 |
| 52 Week High | $1.15 | $6.52 |
Technical Indicators
Market Signals| Indicator | ITOC | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 42.09 |
| Support Level | N/A | $3.28 |
| Resistance Level | $0.34 | $4.24 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 27.82 | 10.23 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.